MedTrace Logo

ProStent Coronary Drug-Eluting Stent

NCT00887211 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2009-04-30

No results posted yet for this study

Summary

A single blind, multi-center, randomized study is preformed to compare ProStent drug-eluting stents with Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd. to evaluate the safety and efficacy of ProStent drug-eluting stent in treating coronary artery lesions.

Conditions

  • Coronary Disease

Interventions

DEVICE

stent

ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.

DEVICE

stent

Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.

Sponsors & Collaborators

  • CCRF Consulting Co., Ltd.

    lead OTHER

Principal Investigators

  • Runlin Gao · Chinese Academy of Medical Sciences, Fuwai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-02-28
Completion
2010-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00887211 on ClinicalTrials.gov